What should you know about immune checkpoint inhibitors for lung cancer?

Checkpoint inhibitors block selected signals that cancers can use to reduce immune activity. Releasing that brake may allow immune cells to respond to lung cancer. The decision depends on the cancer type and stage, tumour test results, previous or planned treatment, and your general health. Some people receive immunotherapy alone, while others have it combined or sequenced with treatments such as chemotherapy or radiotherapy.

Immune treatment can also cause inflammation in healthy organs. The lungs, bowel, liver, skin, thyroid and other hormone glands, kidneys, and nervous system may be affected. The timing and severity vary, so a symptom should be discussed rather than attributed to cancer or treatment without assessment.

Tell the oncology team about autoimmune conditions, organ transplant history, allergies, medicines, supplements, and prior treatments. Ask which tests will be used to check the cancer and monitor organs during treatment. Keep a written symptom diary, including new cough, bowel changes, rash, fatigue, or changes in weight or thirst. Check before starting a medicine, supplement, or vaccine, and keep the urgent contact number accessible.

Contact your oncology team promptly for worsening cough, breathlessness, chest pain, persistent diarrhoea, severe abdominal pain, rash, yellowing of the skin, dark urine, unusual weakness, confusion, headache, or reduced urine. Seek urgent help for severe breathing difficulty, fainting, sudden weakness, or swelling of the face or throat. A hoarse voice may have several causes, but a new or persistent change should be reported and assessed.

What makes a checkpoint inhibitor appropriate for my lung cancer? Is tumour profiling needed before choosing treatment? Will it be combined with chemotherapy, surgery, or radiotherapy? Which symptoms mean I should call immediately? How will treatment response and possible immune effects be checked?